share_log

Summit Therapeutics | 10-Q: Q3 2024 Earnings Report

Summit Therapeutics | 10-Q: Q3 2024 Earnings Report

Summit Therapeutics | 10-Q：2024財年三季報
美股SEC公告 ·  2024/10/30 19:36

Moomoo AI 已提取核心訊息

Summit Therapeutics reported Q3 2024 financial results, with a net loss of $56.3 million. Research and development expenses increased to $37.7 million, primarily due to continued investment in ivonescimab development. The company raised $235 million through a private placement and $44.2 million via an at-the-market offering to fund ongoing operations.Summit completed enrollment in its HARMONi Phase III trial for ivonescimab in NSCLC, with topline results expected in mid-2025. The company plans to initiate the HARMONi-7 Phase III trial in early 2025, comparing ivonescimab monotherapy to pembrolizumab in first-line metastatic NSCLC patients with high PD-L1 expression. Summit also expanded its licensed territories for ivonescimab to include Latin America, Middle East, and Africa.As of September 30, 2024, Summit had $93.8 million in cash and $393.1 million in short-term investments. The company believes its current resources will fund operations for at least the next 12 months. Summit continues to advance ivonescimab's clinical development and explore opportunities in solid tumor settings beyond NSCLC.
Summit Therapeutics reported Q3 2024 financial results, with a net loss of $56.3 million. Research and development expenses increased to $37.7 million, primarily due to continued investment in ivonescimab development. The company raised $235 million through a private placement and $44.2 million via an at-the-market offering to fund ongoing operations.Summit completed enrollment in its HARMONi Phase III trial for ivonescimab in NSCLC, with topline results expected in mid-2025. The company plans to initiate the HARMONi-7 Phase III trial in early 2025, comparing ivonescimab monotherapy to pembrolizumab in first-line metastatic NSCLC patients with high PD-L1 expression. Summit also expanded its licensed territories for ivonescimab to include Latin America, Middle East, and Africa.As of September 30, 2024, Summit had $93.8 million in cash and $393.1 million in short-term investments. The company believes its current resources will fund operations for at least the next 12 months. Summit continues to advance ivonescimab's clinical development and explore opportunities in solid tumor settings beyond NSCLC.
Summit Therapeutics報告了2024年第三季度的財務結果，淨虧損爲5630萬美元。研發費用增加至3770萬美元，主要是由於繼續投資於ivonescimab的開發。該公司通過定向增發籌集了23500萬美元，並通過市場發售籌集了4420萬美元，以資助持續運營。Summit完成了在NSCLC中進行ivonescimab的HARMONi III期試驗的患者入組，預計於2025年中期獲得首要結果。該公司計劃於2025年初啓動HARMONi-7 III期試驗，將ivonescimab單藥治療與 pembrolizumab進行比較，適用於高PD-L1表達的第一線轉移性NSCLC患者。Summ...展開全部
Summit Therapeutics報告了2024年第三季度的財務結果，淨虧損爲5630萬美元。研發費用增加至3770萬美元，主要是由於繼續投資於ivonescimab的開發。該公司通過定向增發籌集了23500萬美元，並通過市場發售籌集了4420萬美元，以資助持續運營。Summit完成了在NSCLC中進行ivonescimab的HARMONi III期試驗的患者入組，預計於2025年中期獲得首要結果。該公司計劃於2025年初啓動HARMONi-7 III期試驗，將ivonescimab單藥治療與 pembrolizumab進行比較，適用於高PD-L1表達的第一線轉移性NSCLC患者。Summit還將ivonescimab的許可範圍擴展到拉丁美洲、中東和非洲。截至2024年9月30日，Summit的現金爲9380萬美元，短期投資爲39310萬美元。該公司相信其當前資源將至少爲未來12個月的運營提供資金。Summit繼續推進ivonescimab的臨牀開發，並探索NSCLC以外實體腫瘤領域的機會。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間